中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 36 Issue 3
Mar.  2020
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2020  >  36(3): 587-591

Regulatory effect of water extract of Jianpi Xiaoji prescription on autophagy of human liver cancer SMMC7721 cells

DOI: 10.3969/j.issn.1001-5256.2020.03.023

  • Guangxi Medical University Cancer Hospital

Research funding:

 

  • Received Date: 2019-12-06
  • Published Date: 2020-03-20
    Abstract
  • Objective To investigate the anti-liver cancer mechanism of water extract of Jianpi Xiaoji prescription and its effect on cell autophagy flow and autophagy-related proteins. Methods SMMC7721 cells were treated with water extract of Jianpi Xiaoji prescription.CCK-8 assay was used to measure cell proliferation; flow cytometry was used to measure cell apoptosis rate; Western blot was used to measure the expression of the autophagy-related proteins Beclin1,LC3,and P62; the formation of autophagosomes and the fusion of autophagosomes and lysosomes were monitored. The independent samples t-test was used for comparison of continuous data between two groups; a one-way analysis of variance was used for comparison between multiple groups,and the least significant difference t-test was used for further comparison between two groups. Results The CCK-8 assay showed that cell proliferation was significantly inhibited at 24,48,72,and 96 hours after the drug was added,and there was a significant difference between the drug treatment group and the control group( t =28. 458,81. 093,85. 328,and 100. 158,all P < 0. 001). Flow cytometry showed that compared with the control group,the drug treatment group had a significant increase in the apoptosis of liver cancer SMMC7721 cells( t =-42. 629,P < 0. 001). Western Blot showed that compared with the control group,the drug treatment group had significantly downregulated expression of Beclin1 and significantly upregulated expression of the autophagy markers LC3-Ⅱ and P62. The flow of autophagosomes to autolysosomes was blocked in the drug treatment group,and there was a significant difference between the drug treatment group and the control group( F = 31. 155,P < 0. 001). Conclusion The water extract of Jianpi Xiaoji prescription can inhibit the proliferation of human liver cancer SMMC-7721 cells and promote apoptosis; meanwhile,it can upregulate the expression of Beclin1,downregulate the expression of LC3 and P62,and block the formation of autophagy flux.

     

    • FullText(HTML)
    • References(23)
  • [1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
    [2] VILLANUEVA A. Hepatocellular carcinoma[J]. New Engl J Med,2019,380(15):1450-1462.
    [3] SPARKMAN J,HERNAEZ R,EL-SERAG HB. Traditional Chinese Medicine to the rescue of allopathic medicine in the coadjuvant treatment of hepatocellular carcinoma[J]. Transl Gastroenterol Hepatol,2018,3:97.
    [4] HUANG ZF. Jianpi Xiaoji Tang[J]. Guangxi J Tradit Chin Med,2004,27(4):32.(in Chinese)黄智芬．健脾消积汤[J]．广西中医药，2004,27(4):32.
    [5] HAUNG ZF,LI HZ,ZHANG ZJ,et al. Effect of Jianpixiaoji decoction on the quality of life of patients with advanced primary liver cancer[J]. Chin J Integrated Tradit West Med Digest,2010,18(1):47-48,50.(in Chinese)黄智芬，黎汉忠，张作军，等．健脾消积汤对晚期原发性肝癌患者生存质量的影响[J]．中国中西医结合消化杂志，2010,18(1):47-48,50.
    [6] TIAN H,ZHU JY,MO XL,et al. Inhibitory effect of Jianpi Xiaoji decoction containing plasma on hepatocellular carcinoma HepG2 cells and its mechanism[J]. Guangxi Med J,2017,39(7):1025-1028.(in Chinese)田昊，诸佳瑜，莫晓丽，等．健脾消积汤含药血浆对肝细胞癌HepG2细胞的抑制作用及其机制[J]．广西医学，2017,39(7):1025-1028.
    [7] KUBISCH J,TUREI D,FOLDVARI-NAGY L,et al. Complex regulation of autophagy in cancer-Integrated approaches to discover the networks that hold a double-edged sword[J].Semin Cancer Biol,2013,23(4):252-261.
    [8] CUI B,YU JM. Autophagy:A new pathway for traditional Chinese medicine[J]. J Asian Nat Prod Res,2018,20(1):14-26.
    [9] ZHANG Z,GAO WH,TIAN XF,et al. Effect of Yiqi Huayu Jiefang on SMCC-7721 autophagy flow in human hepatoma cells based on PI3K/m TOR pathway[J]. Chin J Inf Tradit Chin Med,2019,26(10):45-49.(in Chinese)张振，郜文辉，田雪飞，等．基于PI3K/m TOR通路益气化瘀解毒方对人肝癌细胞SMCC-7721自噬流的影响[J]．中国中医药信息杂志，2019,26(10):45-49.
    [10] LU K,WANG J,SUN ZW. Silica nanopartides induce autophagy dysfunction in HepG2 cells[J]. J Health Toxicol,2017,31(4):267-272.(in Chinese)鲁可，王继，孙志伟．纳米Si O2引起肝细胞自噬功能紊乱的研究[J]．毒理学杂志，2017,31(4):267-272.
    [11] JIANG X,HUANG Y,LIANG X,et al. Metastatic prostate cancer-associated P62 inhibits autophagy flux and promotes epithelial to mesenchymal transition by sustaining the level of HDAC6[J]. Prostate,2018,78(6):426-434.
    [12] METZ P,CHIRAMEL A,CHATEL-CHAIX L,et al. Dengue virus inhibition of autophagic flux and dependency of viral replication on proteasomal degradation of the autophagy receptor p62[J]. J Virol,2015,89(15):8026-8041.
    [13] TURCO E,WITT M,ABERT C,et al. FIP200 claw domain binding to p62 promotes autophagosome formation at ubiquitin condensates[J]. Mol Cell,2019,74(2):330-346. e11.
    [14] SETO S,TSUJIMURA K,HORII T,et al. Autophagy adaptor protein p62/SQSTM1 and autophagy-related gene Atg5 mediate autophagosome formation in response to Mycobacterium tuberculosis infection in dendritic cells[J]. PLo S One,2013,8(12):e86017.
    [15] LOOS B,KLIONSKY DJ,DU TOIT A. On the relevance of precision autophagy flux control in vivo-Points of departure for clinical translation[J]. Autophagy,2019.[Epub ahead of print]
    [16] MA RD,ZHOU GJ,QU M,et al. Corticosterone induces neurotoxicity in PC12 cells via disrupting autophagy flux mediated by AMPK/m TOR signaling[J]. CNS Neurosci Ther,2019,26(2):167-176.
    [17] SONG X,LIU L,CHANG M,et al. NEO212 induces mitochondrial apoptosis and impairs autophagy flux in ovarian cancer[J]. J Exp Clin Cancer Res,2019,38(1):239.
    [18] WANG H,DUAN PW,FU J,et al. Experimental study on the regulation of autophagy in reversing tumor drug resistance by Chinese herbal medicine[J]. Guid J Tradit Chin Med Pharm2019,25(13):53-56.(in Chinese)王浩，段佩雯，伏杰，等．中药单体调控自噬逆转肿瘤耐药的实验研究现状[J]．中医药导报，2019,25(13):53-56.
    [19] LI J,LI X,GAO YY,et al. Research progress of controlling cell autophagy against tumor by traditional Chinese medicine[J]. J Liaoning Univ Tradit Chin Med,2019,6:8-11.(in Chinese)李冀，李想，高彦宇，等．中药调控细胞自噬抗肿瘤研究进展[J]．辽宁中医药大学学报，2019,6:8-11.
    [20] WANG MQ,LI YP,LIU LY,et al. Role and mechanism of autophagy in development and progression of hepatocellular carcinoma and regulation of immunotherapy[J]. J Clin Hepatol,2019,35(5):1129-1134.(in Chinese)王沐淇，李亚萍，刘拉羊，等．自噬在肝细胞癌发生发展和免疫治疗调控中的作用及其机制[J]．临床肝胆病杂志，2019,35(5):1129-1134.
    [21] DU Y,JI X. Bcl-2 down-regulation by small interfering RNA induces Beclin1-dependent autophagy in human SGC-7901cells[J]. Cell Biol Int,2014,38(10):1155-1162.
    [22] GUAN Y,LI Y,ZHAO G,et al. HMGB1 promotes the starvation-induced autophagic degradation of alpha-synuclein in SH-SY5Y cells Atg 5-dependently[J]. Life Sci,2018,202:1-10.
    [23] LISIAK N,TOTON E,RYBCZYNSKA M. Autophagy as a potential therapeutic target in breast cancer treatment[J]. Curr Cancer Drug Targets,2018,18(7):629-639.
    • Relative Articles

  • Relative Articles

    [1]Ru JIA, Pingping ZHANG, Yuan YUAN, Yiyang HU, Qin FENG. Differences and application value of plasma bile acids in tumors of the liver[J]. Journal of Clinical Hepatology, 2024, 40(10): 2042-2048. doi: 10.12449/JCH241018
    [2]Tingting ZHU, Jingshu QI, Yanan GUO, Hongliang LIU, Yanyan TAO, Zhimin ZHAO, Zhengxin LI, Chenghai LIU. Effect of Fuzheng Huayu prescription on hepatocyte extinction and regeneration in a mouse model of liver cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(4): 745-752. doi: 10.12449/JCH240417
    [3]Hui HUANG, Lieming XU, Jian PING, Yang ZHOU. Value of Fuzheng Huayu prescription in preventing liver fibrosis by altering the phenotypic function of CD8+ T lymphocytes in the liver of mice with acute liver injury[J]. Journal of Clinical Hepatology, 2022, 38(2): 342-346. doi: 10.3969/j.issn.1001-5256.2022.02.017
    [4]Lijie MA, Xiaojun ZHU, Jiacheng LIN, Fang WANG, Xuehua SUN, Yueqiu GAO. Mechanism of Lingmao Formula in treatment of chronic hepatitis B based on network pharmacology and animal experiment[J]. Journal of Clinical Hepatology, 2022, 38(7): 1503-1508. doi: 10.3969/j.issn.1001-5256.2022.07.010
    [5]Tian ZHANG, Sijing JIA, Dongxue SUN, Fengxi LONG, Dongxin TANG, Zhu YANG. Mechanism of "Szechwan Chinaberry Fruit-Rhizoma Corydalis" drug combination in treatment of liver cancer based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(9): 2136-2143. doi: 10.3969/j.issn.1001-5256.2021.09.026
    [6]Xi GUAN, Wei LIU, Jiamei CHEN, Yongping MU, Ping LIU, Ying XU. Research advances in the clinical and basic research on Fuzheng Huayu prescription in treatment of chronic liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(6): 1449-1453. doi: 10.3969/j.issn.1001-5256.2021.06.048
    [7]Qiuluo CHENG, Liu LIU, Changchuan BAI, Qingwei CONG, Ying ZHU. Mechanism of action of five classic prescriptions in treatment of hepatocellular carcinoma based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(8): 1848-1855. doi: 10.3969/j.issn.1001-5256.2021.08.020
    [8]Shaohang LAN, Qiuyuan TANG, Nana LI, Ran TAO, Nansheng LIAO, Yinjie MENG, Cao HE, Dewen MAO. Mechanism of action of Xiaochaihu decoction in the treatment of hepatitis B based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(10): 2308-2315. doi: 10.3969/j.issn.1001-5256.2021.10.010
    [9]Le TIAN, Yinghang WANG, Zhi PAN. Mechanism of Xiaozheng Huoluo prescription in preventing liver fibrosis in rats via the ERK5 pathway: An analysis based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(3): 582-589. doi: 10.3969/j.issn.1001-5256.2021.03.016
    [10]ZHANG ZhongLin, YUAN YuFeng. Key operating points of laparoscopic hepatectomy for liver tumor in difficult locations[J]. Journal of Clinical Hepatology, 2020, 36(12): 2663-2666. doi: 10.3969/j.issn.1001-5256.2020.12.006
    [11]Li Jing, Mo JiaHao, Xu HongBin, Zhu JunXia, Shi PeiYu, Xing WanLi, Zhong Chong, Lin LiZhu. Mechanism of action of Sini powder in treatment of liver cancer based on network pharmacology and molecular docking[J]. Journal of Clinical Hepatology, 2020, 36(9): 1998-2004. doi: 10.3969/j.issn.1001-5256.2020.09.018
    [12]Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042
    [13]Wang ZhiYu, Gu SanWei, Chen XiaoQian, Cai YanJun. Clonorchiasis misdiagnosed as hepatic tumor: a case report[J]. Journal of Clinical Hepatology, 2018, 34(3): 602-603. doi: 10.3969/j.issn.1001-5256.2018.03.033
    [14]Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014
    [15]Wang QingLan, Tao YanYan, Lu: Jing, Liu Ping, Liu ChengHai. Antifibrotic mechanism of Fuzheng Huayu prescription by regulation of the differential expression of microRNAs in mouse liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 503-508. doi: 10.3969/j.issn.1001-5256.2016.03.022
    [16]Wang WeiZhen, Meng MingHui, Kong Li, Zhang QingShan, Zhao SuXian, Nan YueMin. Role of Jak /Stat pathway in CCl4- induced rat liver fibrosis model and molecular action mechanism of Fuzheng Huayu recipe in treatment of liver fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(4): 344-348. doi: 10.3969/j.issn.1001-5256.2014.04.014
    [17]Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
    [19]Yang BiWei, Gan YuHong, Ye ShengLong, Zhang BoHeng, Ren ZhengGang, Xia JingLin, Wang YanHong, Ge NingLing, Chen Yi, Li LiXin, Le Fan, Zhang Lan. Necrosis range and safety of radiofrequency combined with systemic chemotherapy and radiofrequency alone.[J]. Journal of Clinical Hepatology, 2004, 20(6): 364-365.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(0)

    Other cited types(1)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 8.9 %FULLTEXT: 8.9 %META: 88.3 %META: 88.3 %PDF: 2.9 %PDF: 2.9 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.4 %其他: 4.4 %China: 0.5 %China: 0.5 %India: 0.2 %India: 0.2 %[]: 0.2 %[]: 0.2 %上海: 4.5 %上海: 4.5 %中卫: 0.2 %中卫: 0.2 %乌鲁木齐: 0.5 %乌鲁木齐: 0.5 %兰州: 0.2 %兰州: 0.2 %北京: 16.6 %北京: 16.6 %南宁: 0.3 %南宁: 0.3 %南阳: 0.2 %南阳: 0.2 %台州: 1.7 %台州: 1.7 %吉林: 0.7 %吉林: 0.7 %哥伦布: 0.2 %哥伦布: 0.2 %大连: 0.2 %大连: 0.2 %广州: 0.5 %广州: 0.5 %张家口: 1.5 %张家口: 1.5 %徐州: 0.2 %徐州: 0.2 %德罕: 0.2 %德罕: 0.2 %悉尼: 0.2 %悉尼: 0.2 %成都: 0.2 %成都: 0.2 %杭州: 1.0 %杭州: 1.0 %格兰特县: 0.2 %格兰特县: 0.2 %武汉: 0.7 %武汉: 0.7 %济南: 0.2 %济南: 0.2 %湖州: 0.3 %湖州: 0.3 %漯河: 0.2 %漯河: 0.2 %芒廷维尤: 39.1 %芒廷维尤: 39.1 %芝加哥: 0.3 %芝加哥: 0.3 %莫斯科: 0.7 %莫斯科: 0.7 %衢州: 1.8 %衢州: 1.8 %西宁: 20.3 %西宁: 20.3 %贵港: 0.2 %贵港: 0.2 %郑州: 0.5 %郑州: 0.5 %都伯林: 0.2 %都伯林: 0.2 %金华: 0.2 %金华: 0.2 %钦州: 0.2 %钦州: 0.2 %长春: 0.5 %长春: 0.5 %长沙: 0.2 %长沙: 0.2 %长治: 0.3 %长治: 0.3 %其他ChinaIndia[]上海中卫乌鲁木齐兰州北京南宁南阳台州吉林哥伦布大连广州张家口徐州德罕悉尼成都杭州格兰特县武汉济南湖州漯河芒廷维尤芝加哥莫斯科衢州西宁贵港郑州都伯林金华钦州长春长沙长治

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1170) PDF downloads(208) Cited by(1)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2462]YesterdayPV[4905]TodayIP[295]TodayPV[698]Online[50]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return